The Significance of Somatostatin Analogues in the Antiproliferative Treatment of Carcinomas

Kath, R.; Höffken, K.

doi:10.1007/978-3-642-59587-5_3

Cited by 14 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…THYROID Volume 16, Number 11, 2006 ª Mary Ann Liebert, Inc. therapeutically beneficial (3). Metabolically stabilized SST analogues were developed for clinical application, namely, octreotide, lanreotide, and vapreotide.…”

Section: Introductionmentioning

confidence: 99%

Is There a Role for Sandostatin Treatment in Patients with Progressive Thyroid Cancer and Iodine-Negative But Somatostatin-Receptor–Positive Metastases?

Kohlfuerst¹,

Igerc²,

Gallowitsch³

et al. 2006

Thyroid

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Is There a Role for Sandostatin Treatment in Patients with Progressive Thyroid Cancer and Iodine-Negative But Somatostatin-Receptor–Positive Metastases?

Kohlfuerst¹,

Igerc²,

Gallowitsch³

et al. 2006

Thyroid

View full text Add to dashboard Cite

show abstract

“…Various animal and human studies have demonstrated that the long‐acting somatostatin analogue octreotide has antitumor effects in patients with various NETs, including malignant PET 18–23. However, many of these studies have limited information for use in the treatment of patients with malignant PETs, in particular for the treatment of patients with malignant gastrinoma 10, 24.…”

mentioning

confidence: 99%

Prospective study of the antitumor efficacy of long‐term octreotide treatment in patients with progressive metastatic gastrinoma

Shojamanesh

Gibril

Louie

et al. 2002

Cancer

200

View full text Add to dashboard Cite

BACKGROUNDMalignant pancreatic endocrine tumors (PETs) have a poor prognosis and existing antitumor treatments are unsatisfactory. Recent studies have shown somatostatin analogues to have antitumor growth effects in patients with malignant PETs; however, to the authors' knowledge, little information exists regarding their efficacy or effect on survival in patients with progressive malignant gastrinoma, the most common symptomatic malignant PET. The purpose of the current study was to study prospectively the efficacy, safety, and effect on survival of long‐term treatment with octreotide in consecutive patients with progressive malignant gastrinoma.METHODSFifteen consecutive patients with malignant gastrinoma with progressive hepatic metastases were studied. All patients underwent conventional imaging studies (computed tomography scan, magnetic resonance imaging, ultrasound, and, if needed, selective angiography) and somatostatin receptor scintigraphy prior to treatment and at 3–6‐month intervals while receiving treatment. The patients all were treated initially with octreotide, 200 μg every 12 hours, and at last follow‐up were being maintained on long‐acting release octreotide, 20–30 mg every month. Tumor size and/or number were used to classify patient responses as either no tumor response or tumor response (stabilization or decrease in size). Treatment response was correlated with tumor and clinical characteristics.RESULTSTumors in 8 of the 15 patients studied (53%) responded at 3 months, with 47% (7 of 15 patients) demonstrating tumor stabilization and 6% (1 of 15 patients) demonstrating a decrease in tumor size. The mean duration of response was 25.0 ± 6.1 months (range, 5.5–54.1 months). Six of the eight responders were continuing to respond at the time of last follow‐up. Tumor response did not correlate with any clinical parameter (e.g., tumor extent, fasting gastrin, or acid secretory rates). However, slow‐growing tumors were more likely to respond prior to treatment (86% vs. 0%) (P < 0.0014). During follow‐up (range, 4–8 years), 25% of the responders died compared with 71% of the nonresponders, a difference that approached statistical significance (P = 0.10). Two patients (13%) developed serious side effects that required the withdrawal of octreotide.CONCLUSIONSOctreotide is an effective antitumor treatment in patients with progressive malignant gastrinoma. In approximately 50% of these patients octreotide has an antigrowth effect; treatment is associated with a low incidence of serious side effects compared with other antitumor treatments commonly used and, in contrast to many studies, the growth response is long‐lasting. The results of the current study suggest that octreotide treatment should replace chemotherapy as the standard treatment for these patients, especially those patients with slow‐growing tumors. Additional studies involving larger numbers of patients will be needed to determine a convincing effect on survival. Cancer 2002;94:331–43. © 2002 American Cancer Society.

show abstract

“…In addition, somatostatin and its analogues are candidates for use as endocrine agents in the treatment of pancreatic adenocarcinoma (Cannobio et al. 1991; Kath et al. 2000).…”

Section: Discussionmentioning

confidence: 99%

“…Pre‐clinical studies have focused on the anticancer effects of somatostatin analogues, especially in pancreatic carcinomas (Cannobio et al. 1991; Kath & Hoffken 2000). However, regardless of the surgical procedure, the radiation therapy technique, the type of chemotherapy and hormonal therapy, or combinations thereof, survival of pancreatic cancer patients remains low, with the major problem one of the local control of disease (Lionetto et al.…”

Section: Introductionmentioning

confidence: 99%

Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma

Kouloulias

Nikita

Kouvaris

et al. 2002

European Journal of Cancer Care

View full text Add to dashboard Cite

The aim of this study was to evaluate the tolerability and the possible clinical benefit of intraoperative hyperthermia combined with multischedule chemotherapy and bypass surgery for the palliative treatment of inoperable pancreatic cancer. Ten patients with unresectable adenocarcinoma of the pancreas received preoperative chemotherapy [5-fluorouracil (5-FU)], bypass surgery and postoperative chemotherapy (5-FU, doxorubicin and cisplatin) plus sandostatin and radiotherapy (45 Gy, 25 fractions, 5 days a week). A single session of intraoperative hyperthermia was performed, by using a waveguide-type applicator (433 MHz). The tumour region was heated to 43-45 degrees C for up to 60 min, while 500 mg 5-FU was infused simultaneously through the gastroduodenal into the splenic artery. Postoperative recovery was uneventful for all patients. A brief instrument was developed for evaluating patients' quality of life. Chemotherapy-related toxicity included myelosuppression, vomiting, alopecia and increase in blood urea nitrogen (BUN), creatinine, SGOT and SGPT. Glucose and amylase determinations remained within normal limits throughout the whole treatment. There was a significant improvement before and 1 month after combined treatment in Eastern Cooperative Oncology Group (ECOG) status (1.8 +/- 0.4), Scott-Huskinsson pain scale (3.2 +/- 0.8) and quality of life score (30.5 +/- 6.7). No progressive disease was noticed and the median overall survival was 11 (SE = 2.4) months. There was also a significant (P = 0.002, Wilcoxon test) decrease in values of both serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9), from 7.6 +/- 1.3 ng/mL and 875.7 +/- 104.8 U/mL to 3.5 +/- 0.7 ng/mL and 65.3 +/- 14.1 U/mL respectively. The first clinical results suggest a potential advantage of using combined intraoperative hyperthermia, chemotherapy and postoperative radiotherapy in the palliative treatment of the adenocarcinoma of the pancreas. The whole procedure seems to be free of perioperative morbidity, while the chemotherapy toxicity was rather moderate. However, the preliminary nature limits the general applicability of our results.

show abstract

The Significance of Somatostatin Analogues in the Antiproliferative Treatment of Carcinomas

Cited by 14 publications

References 34 publications

Is There a Role for Sandostatin Treatment in Patients with Progressive Thyroid Cancer and Iodine-Negative But Somatostatin-Receptor–Positive Metastases?

Is There a Role for Sandostatin Treatment in Patients with Progressive Thyroid Cancer and Iodine-Negative But Somatostatin-Receptor–Positive Metastases?

Prospective study of the antitumor efficacy of long‐term octreotide treatment in patients with progressive metastatic gastrinoma

Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma

Contact Info

Product

Resources

About